Tecogen (NASDAQ: TGEN) director-linked trust buys 5,000 common shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
TECOGEN INC. director Earl Lewis reported an open-market purchase of the company’s common stock through a trust. The trust acquired 5,000 shares at an average price of $2.8817 per share on March 26, 2026. Following this transaction, holdings associated with Lewis total 1,006,006 shares of common stock, indicating a relatively small incremental increase to an already substantial position.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 5,000 shares ($14,409)
Net Buy
1 txn
Insider
Lewis Earl
Role
Director
Bought
5,000 shs ($14K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 5,000 | $2.8817 | $14K |
Holdings After Transaction:
Common Stock — 1,006,006 shares (Direct)
Footnotes (1)
- [object Object]
FAQ
What insider transaction did TECOGEN INC. (TGEN) disclose for Earl Lewis?
TECOGEN INC. reported that a trust associated with director Earl Lewis bought 5,000 shares of common stock in an open-market transaction. The shares were purchased at an average price of $2.8817 per share, increasing his reported holdings in the company.
What are Earl Lewis’s total reported TECOGEN INC. (TGEN) holdings after this transaction?
After the 5,000-share purchase, holdings associated with Earl Lewis total 1,006,006 TECOGEN INC. common shares. This figure includes the newly acquired shares and represents his reported position immediately following the disclosed transaction.
Was the TECOGEN INC. (TGEN) insider transaction made directly by Earl Lewis?
The filing notes that the 5,000 TECOGEN INC. shares were "acquired by a trust." This indicates the transaction was executed through a trust associated with director Earl Lewis rather than directly in his personal name.
Does the TECOGEN INC. (TGEN) Form 4 include any derivative securities activity?
The Form 4 data show no derivative security transactions for this event. The filing reports only a non-derivative common stock purchase, with no listed option exercises, conversions, or other derivative-related entries in the summarized information.